ArticleInternational journal of clinical pharmacy2026
Concurrent use of medicines with similar adverse drug reaction profiles in older adults: identifying potential deprescribing opportunities using population-level dispensing data.
Article in International journal of clinical pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A qualitative analysis to identify implementation strategies for a deprescribing clinical practice guideline using the CFIR-ERIC Matching Tool: perspectives from consumers and professional stakeholders.International journal of clinical pharmacy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOlder adults are more vulnerable to medicine-related harm. Identifying concurrent use of medicines with similar adverse drug reaction (ADR) profiles may support opportunities for safer prescribing and deprescribing.
aimTo examine the frequency of concurrent use of medicines with overlapping ADR profiles in older adults. A secondary aim was to examine the contribution of potentially inappropriate medicine (PIMs) to overlapping ADR profiles.
methodWe used data from the 10% sample of dispensing claims from the Australian Pharmaceutical Benefits Scheme between April and June 2022. Medicines were classified by ADR risk using an adapted version of the 2018 Scottish cumulative toxicity tool, which identifies 13 ADR types based on product information. PIMs were identified using the 2024 Australian PIMs list. Individuals aged 65 years or older who were dispensed at least one medicine associated with a listed ADR were included. The outcome of interest was the percentage of persons with an overlapping ADR (dispensed at least two medicines associated with the same ADR). A secondary analysis examined changes in overlapping ADR profiles under a hypothetical scenario excluding PIMs.
resultsOur analysis included 323,599 older adults, of which 75.5% (n = 244,331) had at least one overlapping ADR risk, while 64% (n = 206,815) had two or more overlapping ADR risks. Falls/fractures 70.1% (n = 226,873), constipation 53.5% (n = 173,287), and renal injury 38.5% (n = 124,471) were the most common overlapping ADR risks. Under a hypothetical scenario excluding PIMs, an additional 13,803 people would have no falls/fracture overlapping ADR risk, and 19,396 would have no overlapping ADR risk.
conclusionConcurrent use of medicines with similar ADR profiles is common among older adults. Structured tools to identify the use of medicines with similar ADR risks may support deprescribing and safer medicine use in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.